Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION)

Next Previous
Trial Profile

A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Oleclumab (Primary)
  • Indications Non-small cell lung cancer; Renal cell carcinoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms DOMINATION

Most Recent Events

  • 13 Nov 2020 Status changed from not yet recruiting to withdrawn prior to enrolment, as Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types anddoes not support further evaluation of this doublet.
  • 12 Aug 2020 Planned End Date changed from 2 Mar 2023 to 1 Jan 2024.
  • 12 Aug 2020 Planned primary completion date changed from 2 Mar 2023 to 1 Jan 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top